LOS ANGELES / ACCESSWIRE / February 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ('Invivyd' or 'the Company') (NASDAQ:IVVD), ADGI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between November 29, 2021 and December 14, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before April 3, 2023.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Invivyd's studies and analyses that it claimed to demonstrate ADG20's effectiveness against the Omicron variant were unreliable and ineffective. The Company's claims about the effectiveness of ADG20 were not supported by facts. In fact, ADG20 was 300 times less effective against Omicron as against prior variants of COVID-19. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Invivyd, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contact:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE: The Schall Law Firm